The more assumptions you have to make, the more unlikely an explanation is.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, "of late" OMER has tried my patience, but up 100% since Nov. I also expect higher this year although how it travels to get there is anyone's guess. NLST just hit a 2 yr high touching on $1. I expect the moon from NLST. Started buying high .40s bought along the way up and sold small once when I pushed the wrong button chuckle. Edit now high of 1.02
AVXL! very nice move! you have been having some fun. congrats.
“What is a Case Management Conference? The Case Management Conference (also called the "Early Case Evaluation") is an initial hearing where the judge, the attorneys, and the parties meet to discuss the issues involved in the case. The whole purpose is to get your case moving forward.”
I’m betting a date to pick up where they left off, the Markman Hearing, will be set.
So it "publishes" on Monday.
Me too, I refuse to voluntarily invite an (intentional) idiot into my office.
Excellent post Apophis, important info.
maybe also could be smart money with mm help (possibly) accumulating cheap.
Your welcome frank, just passing on what i find. my take on the pps is we should already be at $2.13ish the 5yr high (by the oldest chart available to me maybe 7yr high). holy cow where is the value for having won the patents challenge?
NICE! you go judge(sir)
morning i would say that TX judge is done with frivolous delays
thumb up :)
Yes and Markman moved up 3 wks to March 1
Happy dance!
motion by Sk to move to CA was denied.
https://stocktwits.com/jmcai273/message/282767018
Very clear, yeah g trampled on NLST to get where they are.
Nicely done! “there is some speculation that Amazon has as many servers as google... “
.....and the # continues to grow! I would like to wander through a 1,000,000 sq foot server facility...once.
It’s there.
Thank-you ST, been doing some serious paddling. All is well and
hope that's true for you too.
They may be waiting for the flavor of the Markman hearing, even though there is a very good chance the judge will make it clear that settlement is in g’s best interest.
Our courts are supposed to support swift justice and at this time most would view Hong et al as long suffering. Fortunately all the speculation can be over at anytime once the request to lift stay is granted.
“Markman hearings are important, because the court determines patent infringement cases by the interpretation of claims. A Markman hearing may encourage settlement, because the judge's claim construction finding can indicate a likely outcome for the patent infringement case as a whole.”
The why is in the description of a Markman hearing. How do we get there (Markman)? I remember 2 things lift stay so that a scheduling hearing can be held. Well 3 things if you count publishing of recertification.
Very interesting article on royalties in infringement cases:
Centripetal Networks v. Cisco: A Perspective on Ongoing Royalty Awards for Patent Infringement
https://www.americanbar.org/groups/litigation/committees/business-torts-unfair-competition/practice/2020/centripetal-networks-v-cisco/
Did this happen? This alignment between USPTO and Federal Courts? Top of search for IRPS as USPTO.
Posted at May 8, 2018 in Claim Construction, Covered Business Method Patents, Inter partes review, Post Grant Review by Todd S. Werner Share
Less than two months after Andrei Iancu was confirmed as the new Director of the USPTO, the Office issued a Notice of Proposed Rulemaking concerning the claim construction standards employed in contested USPTO proceedings, including IRPs, PGRs, and CBMs. The proposed change would abandon the broadest reasonable construction standard currently used for unexpired patents in favor of the same approach used by federal courts under Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (en banc). The proposed rule would instruct the PTAB to consider any claim construction rulings in federal court or ITC proceedings that are “timely made of record.” The stated rationales for the proposed change include improved judicial efficiency and harmonization of the federal court and USPTO constructions, as patents subjected to contested PTO proceedings are often concurrently litigated in federal courts. The USPTO intends for the new standard to be applied in all matters that are pending when the final rule is passed.
Public comments will be accepted for 60 days following the official publication of the proposed rule, which is expected to be published May 9, 2018. The preferred method for offering comments is by email to PTABNPR2018@uspto.gov. All comments submitted directly to the USPTO or provided on the Federal eRulemaking Portal should include the docket number (PTO-P-2018-0036).
The change in construction standards will not have a significant impact in all contested PTO proceedings, but it should make it more difficult to invalidate some claims, as narrower constructions will read on less prior art.
What does IRPS as USPTO mean?
Right one has to be able to not obsess over the waiting.
Well fortunately N v google is post all that sorting out stuff (11 yrs). Federal Appeals has ruled and google has declined a trip to SCOTUS. There is no question about what State to hold proceeding and ruling on patent 912 is definitive.
Stock has been in an uptrend since 12/21.
Not new news but I like the smart reporting style:
Omeros's Biologics License Application for Blood Vessel Damage Treatment Candidate Accepted for Priority Review by FDA
1/19/21, 8:06 AM
10:06 AM EST, 01/19/2021 (MT Newswires) -- Omeros (OMER) said Tuesday its biologics license application for narsoplimab, a potential treatment for transplant-associated thrombotic microangiopathy, has been accepted for priority review by the US Food and Drug Administration.
Thrombotic microangiopathy is characterized by a pattern of damage in the small blood vessels.
The FDA has set the Prescription Drug User Fee Act action date on July 17.
This is great info for those of us not clear on how courts work.
Every event is one step closer to............
A Markman hearing is a pretrial hearing in a U.S. District Court during which a judge examines evidence from all parties on the appropriate meanings of relevant key words used in a patent claim, when patent infringement is alleged by a plaintiff. It is also known as a "Claim Construction Hearing".[1]
Holding a Markman hearing in patent infringement cases has been common practice since the U.S. Supreme Court, in the 1996 case of Markman v. Westview Instruments, Inc., found that the language of a patent is a matter of law for a judge to decide, not a matter of fact for a jury to decide. In the United States, juries determine facts in many situations,[2] but judges determine matters of law.[3][4]
Markman hearings are important, because the court determines patent infringement cases by the interpretation of claims. A Markman hearing may encourage settlement, because the judge's claim construction finding can indicate a likely outcome for the patent infringement case as a whole. Markman hearings are before a judge, and generally take place before trial. A Markman hearing may occur before the close of discovery, along with a motion for preliminary injunction, or at the end of discovery, in relation to a motion for summary judgment. A Markman hearing may also be held after the trial begins, but before jury selection.[5]
The evidence considered in a Markman hearing falls into two categories: intrinsic and extrinsic. Intrinsic evidence consists of the patent documentation and any prosecution history of the patent. Extrinsic evidence is testimony, expert opinion, or other unwritten sources; extrinsic evidence may not contradict intrinsic evidence.[6]
well shoot, thanks for sharing
NLST consolidated a little more info added to a short term overview:
Have you looked at NLST?
Short story:
*google signed a NDA with NLST to use their seminal technology
*google was bad even lied to court
*they lost their appeal
*google let date to file with scotus pass
*now one way or another they must pay
*one way to pay--google's case and settlement with ADT(eye opening)
*another way to pay-- Centripetal v Cisco (cisco was bad for 3 yrs
google is on the hook for 11 yrs)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160597164
*estimate to file to lift stay Q1 2021
*bought dips as low as .48 keep adding
*yahoo board and ihub board are bullish
lots of speculation but also good info.
*there are active cases with other companies
*Sk-Hynix scheduled Markman hearing for infringement of (NLST)patents 218, 525 and 595 3/9/2021
trial, if defendants choose, 12/2021
*besides the coming Markman, SK recently lost to Netlist on appeal for 2 claims 40 & 41 on patent 907
*"Patent 907 found to be patentable against SK Hynix due to 2 claims" posted MilitaryDeal
*it is a popping year for NLST they have been chasing google in court for 11 yrs, google will have to settle.
Found this on another board, perhaps it has already been posted, if so tough shit lol jk. I appreciated the analysist due to my ignorance of the "non-volatile dual in-line memory module market size" and thought others might as well.
https://www.grandviewresearch.com/industry-analysis/non-volatile-dual-in-line-memory-module-market
I think this is it, an agreement between N and google to proceed to publish the recert. That is how I interpret it anyway:
https://stocktwits.com/jmcai273/message/277389146
Getting close!
Have you looked at NLST? Short story:
*google signed a NDA with NLST to use their seminal technology
*google was bad even lied to court
*they lost their appeal
*google let date to file with scotus pass
*now one way or another they must pay
*one way to pay--google's case and settlement with ADT(eye opening)
*another way to pay-- Centripetal v Cisco (cisco was bad for 3 yrs
google is on the hook for 11 yrs)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160597164
*estimate to file to lift stay Q1 2021
*bought dips as low as .48 keep adding
*yahoo board and ihub board are bullish
lots of speculation but also good info.
*there are active cases with other companies Sk-hynic recently lost
on 2 parts of patent 907
*scheduled markman for infringement of (NLST)patents 218 and 595 3/9/2021
trial, if defendants choose, 12/2021
*it is a popping year for NLST they have been chasing google in court for 11 yrs, google will have to settle.
I think that's realistic.
LOL!!! That's awesome! I thought you were a newbie! Yay for us! It is going to blow up one of these days. It is doing well today.
I tried to find the link to the new slide deck related to the JPM presentation. Not working out for me right now but found a pertinent
slide here:
https://stocktwits.com/cdm85/message/276377372
Notice under MASP-2 lectin pathway it has Covid -19 as end of P2.
The only way I can understand this is through the experience of the CEO transforming a P2 in Narsoplimad into a P3 do to the overwhelming positive data. If you did not know, Omeros has be continuing to treat very ill Covid patients with promising results.
I can't give you a %. What I can do is encourage you to consider including
in you pondering the fact that OMER will be participating in this:
https://www.ispytrials.org/collaborate/covid-19-updates. So far narsoplimad is the only monoclonal antibody invited. And news could come from FDA or this event. I encourage you to listen to JBM presentation below:
https://investor.omeros.com/events/event-details/omeros-corporation-39th-annual-jp-morgan-healthcare-conference
Market likes this news.
OMER JPM slide deck:
https://investor.omeros.com/static-files/5510ef5f-c71d-4b84-9caa-14ca24c240af